Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | BMC Cancer

Figure 1

From: Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients

Figure 1

a) Cancer-specific survival (Kaplan-Meier) for all RCC patients plotted against the pre-operative CRP-group. The 5-year survival rate was 89.4%, 77.9%, and 49.5% for all evaluable patients (n = 1,047) with a CRP of ≤4 mg/l (n = 558), 4–10 mg/l (n = 141), and >10 mg/l (n = 348), respectively (p < 0.001, log rank). b) Overall survival (Kaplan-Meier) for all RCC patients plotted against the pre-operative CRP-group. The 5-year survival rate was 85.5%, 71.1%, and 46.3% for all evaluable patients (n = 1,133) with a CRP of ≤4 mg/l (n = 603), 4–10 mg/l (n = 158), and >10 mg/l (n = 372), respectively (p < 0.001, log rank).

Back to article page